IDOH Updates on Monoclonal Antibodies and Veklury (Remdesivir)

Feb. 4, 2022

Monoclonal Antibody Infusion Update: The only mAb infusion effective against the Omicron variant is GSK's sotrovimab. Allocations of Bamlanivimab/Etesevimab and Regeneron therapeutics have been paused. Providers should stop prescribing Regeneron and Bamlanivimab/Etesevimab infusions at this time, as there is no expected benefit but a risk of side effects remains.

Veklury (remdesivir) Update: The FDA has expanded the approved indication for Veklury to include its use in adults and pediatric patients (12 years of age and older who weigh at least 40 kilograms, which is about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

The FDA also revised the EUA for Veklury to additionally authorize the drug for treatment of pediatric patients weighing 3.5 kilograms to less than 40 kilograms or pediatric patients less than 12 years of age weighing at least 3.5 kilograms, with positive results of direct SARS-CoV-2 viral testing, and who are not hospitalized and have mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.